Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects»
The meeting of experts discussed the clinical and pathophysiological features of secondary progressive multiple sclerosis (MS) (SPMS), clinical trials, and promising treatments for the progressive MS stage, as well as proposals contributing to the improvement of the current state of the problem of S...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2019-12-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/1230 |
| _version_ | 1797876330640965632 |
|---|---|
| author | N. V. Khachanova A. N. Boyko K. Z. Bakhtiyarova Ya. V. Vlasov E. P. Evdoshenko S. A. Sivertseva T. E. Schmidt M. V. Shumilina |
| author_facet | N. V. Khachanova A. N. Boyko K. Z. Bakhtiyarova Ya. V. Vlasov E. P. Evdoshenko S. A. Sivertseva T. E. Schmidt M. V. Shumilina |
| author_sort | N. V. Khachanova |
| collection | DOAJ |
| description | The meeting of experts discussed the clinical and pathophysiological features of secondary progressive multiple sclerosis (MS) (SPMS), clinical trials, and promising treatments for the progressive MS stage, as well as proposals contributing to the improvement of the current state of the problem of SPMS. In particular, the definition of and criteria for SPMS are formulated; the earliest period, when its confirmed progression can be recorded, is stated to be 3 months. The exacerbation-unaffected disability progression confirmed 6 months later may be considered to be more convincing. The introduction of tools for the early assessment of disability progression into routine practice will be able to identify the signs of progression at an earlier stage in order to timely change treatment policy. It is also noted that therapeutic possibilities in establishing secondary progression, especially in the absence of exacerbations, but in maintaining progression, are still insufficient. Certain hopes for slowing the progression in patients with SPMS are associated with the advent of siponimod, a new molecular class of S1P receptor modulators. The confirmed efficiency of siponimod in a large population of patients with SPMS allows the latter to be recommended for its treatment with both persistent disease activity (SPMS with exacerbations) and disability progression without exacerbations (SPMS without exacerbations). |
| first_indexed | 2024-04-10T02:01:32Z |
| format | Article |
| id | doaj.art-021d770c1f7a43a9ba13399f83a8e051 |
| institution | Directory Open Access Journal |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| last_indexed | 2024-04-10T02:01:32Z |
| publishDate | 2019-12-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj.art-021d770c1f7a43a9ba13399f83a8e0512023-03-13T08:42:19ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422019-12-0111417217510.14412/2074-2711-2019-4-172-175942Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects»N. V. Khachanova0A. N. Boyko1K. Z. Bakhtiyarova2Ya. V. Vlasov3E. P. Evdoshenko4S. A. Sivertseva5T. E. Schmidt6M. V. Shumilina7Department of Neurology, Neurosurgery, and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaDepartment of Neurology, Neurosurgery, and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Department of Neuroimmunology, Federal Center for Cerebrovascular Pathology and Stroke, Ministry of Health of RussiaBashkir State Medical University, Ministry of Health of RussiaDepartment of Neurology and Neurosurgery, Samara State Medical University, Ministry of Health of RussiaCity Center for Multiple Sclerosis City Clinical Hospital Thirty-One«Neftyanik» Primary Healthcare Unit, Tyumen Regional Center for Multiple SclerosisDepartment of Nervous System Diseases and Neurosurgery, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaCity Center for Multiple Sclerosis City Clinical Hospital Thirty-OneThe meeting of experts discussed the clinical and pathophysiological features of secondary progressive multiple sclerosis (MS) (SPMS), clinical trials, and promising treatments for the progressive MS stage, as well as proposals contributing to the improvement of the current state of the problem of SPMS. In particular, the definition of and criteria for SPMS are formulated; the earliest period, when its confirmed progression can be recorded, is stated to be 3 months. The exacerbation-unaffected disability progression confirmed 6 months later may be considered to be more convincing. The introduction of tools for the early assessment of disability progression into routine practice will be able to identify the signs of progression at an earlier stage in order to timely change treatment policy. It is also noted that therapeutic possibilities in establishing secondary progression, especially in the absence of exacerbations, but in maintaining progression, are still insufficient. Certain hopes for slowing the progression in patients with SPMS are associated with the advent of siponimod, a new molecular class of S1P receptor modulators. The confirmed efficiency of siponimod in a large population of patients with SPMS allows the latter to be recommended for its treatment with both persistent disease activity (SPMS with exacerbations) and disability progression without exacerbations (SPMS without exacerbations).https://nnp.ima-press.net/nnp/article/view/1230secondary progressive multiple sclerosisdisabilityconfirmed progressiontherapy |
| spellingShingle | N. V. Khachanova A. N. Boyko K. Z. Bakhtiyarova Ya. V. Vlasov E. P. Evdoshenko S. A. Sivertseva T. E. Schmidt M. V. Shumilina Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects» Неврология, нейропсихиатрия, психосоматика secondary progressive multiple sclerosis disability confirmed progression therapy |
| title | Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects» |
| title_full | Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects» |
| title_fullStr | Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects» |
| title_full_unstemmed | Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects» |
| title_short | Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects» |
| title_sort | recommendations from the expert meeting secondary progressive multiple sclerosis unresolved issues and prospects |
| topic | secondary progressive multiple sclerosis disability confirmed progression therapy |
| url | https://nnp.ima-press.net/nnp/article/view/1230 |
| work_keys_str_mv | AT nvkhachanova recommendationsfromtheexpertmeetingsecondaryprogressivemultiplesclerosisunresolvedissuesandprospects AT anboyko recommendationsfromtheexpertmeetingsecondaryprogressivemultiplesclerosisunresolvedissuesandprospects AT kzbakhtiyarova recommendationsfromtheexpertmeetingsecondaryprogressivemultiplesclerosisunresolvedissuesandprospects AT yavvlasov recommendationsfromtheexpertmeetingsecondaryprogressivemultiplesclerosisunresolvedissuesandprospects AT epevdoshenko recommendationsfromtheexpertmeetingsecondaryprogressivemultiplesclerosisunresolvedissuesandprospects AT sasivertseva recommendationsfromtheexpertmeetingsecondaryprogressivemultiplesclerosisunresolvedissuesandprospects AT teschmidt recommendationsfromtheexpertmeetingsecondaryprogressivemultiplesclerosisunresolvedissuesandprospects AT mvshumilina recommendationsfromtheexpertmeetingsecondaryprogressivemultiplesclerosisunresolvedissuesandprospects |